SEPT9 is altered in 0.06% of all cancers with colon adenocarcinoma, endometrial endometrioid adenocarcinoma, acute myeloid leukemia, breast invasive ductal carcinoma, and colorectal mucinous adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in SEPT9 are SEPT9 A100T (0.85%), SEPT9 A571S (0.39%), SEPT9 E393Q (0.22%), SEPT9 I114M (0.85%), and SEPT9 I397V (0.22%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.